Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In Vivo Circular RNA CAR-T Cell Therapy in R/R B-Cell Malignancies
NCT07774572Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in B cell lymphoma, chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM), sponsored by Ruijin Hospital. Primary endpoints: Incidence and severity of treatment-emergent adverse events at 24 weeks and Incidence of dose-limiting toxicities at 28 days. Started May 2026; status: recruiting.
02
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT07774572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07774572.